LEADER 03947nam 22005895 450 001 9910253910703321 005 20200701075728.0 010 $a3-319-58290-9 024 7 $a10.1007/978-3-319-58290-0 035 $a(CKB)3710000001404499 035 $a(DE-He213)978-3-319-58290-0 035 $a(MiAaPQ)EBC4871546 035 $a(PPN)202987981 035 $a(EXLCZ)993710000001404499 100 $a20170605d2017 u| 0 101 0 $aeng 135 $aurnn|008mamaa 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aPharmacologic Therapy of Ocular Disease /$fedited by Scott M. Whitcup, Dimitri T. Azar 205 $a1st ed. 2017. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2017. 215 $a1 online resource (VIII, 394 p.) 225 1 $aHandbook of Experimental Pharmacology,$x0171-2004 ;$v242 311 $a3-319-58288-7 320 $aIncludes bibliographical references at the end of each chapters and index. 327 $aGeneral Principles: Principles of Ocular Pharmacology -- Ocular Pharmacokinetics -- Ocular Drug Delivery -- Anterior Segment and Tear Film: Tear Film-dry eye -- Conjunctiva-allergic conjunctivitis, infectious conjunctivitis, conjunctival hyperemia -- Cornea-Keratitis, antibiotics, antifungals, anti-virals, anti-inflammatory agents including corticosteroids and NSAIDS -- Cornea-Keratoconus and other corneal disease, Pharmacologic cross-linking and future therapy -- Lens-management of cataract surgery, cataract prevention, floppy iris syndrome -- Trabecular Meshwork and Uvea: Glaucoma-Intraocular Pressure Reduction -- Glaucoma-Neuroprotection -- Uveitis -- Posterior Segment and Optic Nerve: Retina Anti-angiogenesis, AMD, Myopia, DME -- Retina Anti-inflammatory therapy, corticosteroids, anti-complement, AMD, DME -- Atrophic AMD -- Hereditary Retinal Disease -- Optic Nerve. 330 $aThere have been major advancements in the pharmacologic treatment of eye diseases over the past decade. With newly discovered disease targets and novel approaches to deliver therapeutic compounds to the eye, patients are seeing improved outcomes. Not only are there better treatments for diseases where treatments existed, we now have effective therapy for previously untreatable and blinding eye disorders. This volume will cover the pharmacologic treatment of eye diseases from the front of the eye including eyelids, conjunctiva and cornea all the way back to the retina and optic nerve. The first section of the volume reviews general principles of ocular pharmacology, pharmacokinetics, pharmaceutical sciences, and drug delivery. In addition, the volume provides an up to date guide to the pharmacologic approach to the key eye diseases that threaten sight or ocular function. 410 0$aHandbook of Experimental Pharmacology,$x0171-2004 ;$v242 606 $aPharmacology 606 $aPharmaceutical technology 606 $aOphthalmology 606 $aPharmacology/Toxicology$3https://scigraph.springernature.com/ontologies/product-market-codes/B21007 606 $aPharmaceutical Sciences/Technology$3https://scigraph.springernature.com/ontologies/product-market-codes/B21010 606 $aOphthalmology$3https://scigraph.springernature.com/ontologies/product-market-codes/H44004 615 0$aPharmacology. 615 0$aPharmaceutical technology. 615 0$aOphthalmology. 615 14$aPharmacology/Toxicology. 615 24$aPharmaceutical Sciences/Technology. 615 24$aOphthalmology. 676 $a617.7 702 $aWhitcup$b Scott M$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aAzar$b Dimitri T$4edt$4http://id.loc.gov/vocabulary/relators/edt 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910253910703321 996 $aPharmacologic therapy of ocular disease$91764276 997 $aUNINA